Specific heat of robust Nb2PdS5 superconductor

We report specific heat under different magnetic fields for recently discovered quasi-one dimensional Nb2PdS5 superconductor. The studied compound is superconducting below 6 K. Nb2PdS5 is quite robust against magnetic field with dHc/dT of -42 kOe/K. The estimated upper critical field [Hc2(0)] is 190 kOe, clearly surpassing the Pauli-paramagnetic limit of 1.84Tc. Low temperature heat capacity in superconducting state of Nb2PdS5 under different magnetic fields showed s-wave superconductivity with two different gaps. Two quasi-linear slopes in Somerfield-coefficient as a function of applied magnetic field and two band behavior of the electronic heat capacity demonstrate that Nb2PdS5 is a multiband su-perconductor in weak coupling limit with deltagamma/deltaTc=0.9.Comment: 4 pages text Figs. Short Letter MS. Letter-J. Sup. & Novel Ma

PdTe a 4.5K Type II BCS Superconductor

We report on the structure and physical properties of bulk Palladium Tellurium superconductor, which is synthesized via quartz vacuum encapsulation technique at 750 C. The as synthesized compound is crystallized in hexagonal crystal structure. Magnetization and Magneto-transport measurements provided the values of lower and upper critical field to be 250 and 1200 Gauss respectively at 2 Kelvin. The Coherence length and GL parameter are estimated from the experimentally determined upper and lower critical fields, which are 45 nm and 1.48 respectively. The jump in Cp(T) at Tc is found to be 1.33 and the Debye temperature and electronic specific heat constant are 203 Kelvin and 6.01mJ/mole-K2 respectively.Comment: 13 pages Text + Figs: Accepted in Sup. Sci. and Tec

STROKE AS A FIRST PRESENTATION OF MALIGNANCY

Stroke is a frequent complication in patients with cancer occurring in nearly 15% of the cases. However cerebrovascular disease as the first presentation of malignancy has rarely been reported. We report two such cases who were admitted with acute stroke but were later on found to be having malignancy. Routine workup was unrewarding in both patients. Both patients developed pulmonary embolism as well during hospital stay suggesting hypercoagulable state as likely etiology. Reaching to the final diagnosis was an arduous journey but can help guide other clinicians facing similar cases. Non Hodgkins B cell lymphoma and Carcinoma Gall bladder were the final diagnosis in our patients. Therefore, we recommend workup for malignancy if no likely cause is found on routine extensive workup before labelling stroke as cryptogenic stroke. Ultrasound abdomen was particularly rewarding in our patients

Superconductivity at 4.4K in PdTe2-chains of a Ta Based Compound

Superconductivity in PdTe2 heavy transition metal based compounds is rapidly developing field in condensed matter physics community. Here, we report superconductivity in a nominal ternary telluride Ta2Pd0.97Te6 compound, which is synthesized in sealed evacuated quartz ampoule. The resultant compound is crystallized in layered monoclinic Ta4Pd3Te16 phase with space group C2/m, having lattice parameters a=21.304(6)A, b=3.7365(7)A, and c=17.7330A with Beta =120.65(1)degree. Both transport and magnetic measurements demonstrated bulk superconductivity at 4.4K in studied polycrystalline sample. The metallic normal state conductivity can be well ascribed to Fermi-liquid behaviour. The superconducting upper critical field of the compound is determined to be 5.5Tesla based on magneto-restively measurements.Comment: 10 pages text+Fig

Weak ferromagnetism in non-centrosymmetric BiPd 4K superconductor

We report synthesis of non-centrosymmetric BiPd single crystal by self flux method. The BiPd single crystal is crystallized in monoclinic structure with the P21 space group. Detailed SEM (Scanning Electron Microscopy) results show that the crystals are formed in slab like morphology with homogenous distribution of Bi and Pd. The magnetic susceptibility measurement confirmed that the BiPd compound is superconducting below 4K. Further, BiPd exhibits weak ferromagnetism near the superconducting transition temperature in isothermal magnetization (MH) measurements. The temperature dependent electrical resistivity also confirmed that the BiPd single crystal is superconducting at Tc=4K. Magneto transport measurements showed that the estimated Hc2(0) value is around 7.0kOe. We also obtained a sharp peak in heat capacity Cp(T) measurements at below 4K due to superconducting ordering. The normalized specific-heat jump, DC/{\gamma}Tc, is 1.52, suggesting the BiPd to be an intermediate BCS coupled superconductor. The pressure dependent electrical resistivity shows the Tc decreases with increasing applied pressure and the obtained dTc/dP is -0.62K/Gpa.Comment: 11 pages Text+Fig

Prevalence of Color Blindness in Undergraduates of Kathmandu University

Introduction: Color blindness is X-linked recessive inherited disorder that occurs mostly in males and is transmitted through females. Many people with color blindness may remain undetected. Thus the present study aims to evaluate the incidence of color blindness among undergraduates of Kathmandu University. Methods: A cross-sectional study was conducted among 825 undergraduates, aged 17-25 years, from June to August 2018, in Kathmandu University, Kavre, Nepal. The Ishihara plates were used to evaluate the color vision of students under natural day light condition. Results: Study revealed that 24 (2.9%) undergraduates were color blind which include 24 male (5%) and no female. Among the color blind, five (20.3%), three (12.5%), two (8.33%) and 14 (58.33%) males were the victims of deuteranomaly, deuteranopia, protanomalia and total color blindness respectively. Color blindness is prevalent among the Brahmin 10 (3.9%), followed by Chettri 10 (2.72%) and Newar 4 (2.24%). Conclusions: Prevalence of color blindness is found to be higher in males 24 (5%) than females 0 (0%). Total color blindness is the most prevalent in our study. Screening enables the students to become aware of limitations and devise ways of overcoming them

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer

<p>Abstract</p> <p>Background</p> <p>The CyberKnife is an appealing delivery system for hypofractionated stereotactic body radiation therapy (SBRT) because of its ability to deliver highly conformal radiation therapy to moving targets. This conformity is achieved via 100s of non-coplanar radiation beams, which could potentially increase transitory testicular irradiation and result in post-therapy hypogonadism. We report on our early experience with CyberKnife SBRT for low- to intermediate-risk prostate cancer patients and assess the rate of inducing biochemical and clinical hypogonadism.</p> <p>Methods</p> <p>Twenty-six patients were treated with hypofractionated SBRT to a dose of 36.25 Gy in 5 fractions. All patients had histologically confirmed low- to intermediate-risk prostate adenocarcinoma (clinical stage ≤ T2b, Gleason score ≤ 7, PSA ≤ 20 ng/ml). PSA and total testosterone levels were obtained pre-treatment, 1 month post-treatment and every 3 months thereafter, for 1 year. Biochemical hypogonadism was defined as a total serum testosterone level below 8 nmol/L. Urinary and gastrointestinal toxicity was assessed using Common Toxicity Criteria v3; quality of life was assessed using the American Urological Association Symptom Score, Sexual Health Inventory for Men and Expanded Prostate Cancer Index Composite questionnaires.</p> <p>Results</p> <p>All 26 patients completed the treatment with a median 15 months (range, 13-19 months) follow-up. Median pre-treatment PSA was 5.75 ng/ml (range, 2.3-10.3 ng/ml), and a decrease to a median of 0.7 ng/ml (range, 0.2-1.8 ng/ml) was observed by one year post-treatment. The median pre-treatment total serum testosterone level was 13.81 nmol/L (range, 5.55 - 39.87 nmol/L). Post-treatment testosterone levels slowly decreased with the median value at one year follow-up of 10.53 nmol/L, significantly lower than the pre-treatment value (<it>p </it>< 0.013). The median absolute fall was 3.28 nmol/L and the median percent fall was 23.75%. There was no increase in biochemical hypogonadism at one year post-treatment. Average EPIC sexual and hormonal scores were not significantly changed by one year post-treatment.</p> <p>Conclusions</p> <p>Hypofractionated SBRT offers the radiobiological benefit of a large fraction size and is well-tolerated by men with low- to intermediate-risk prostate cancer. Early results are encouraging with an excellent biochemical response. The rate of new biochemical and clinical hypogonadism was low one year after treatment.</p

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570